Target dark spots in as little as three days with the Abib Glutathiosome Dark Spot Pad Vita Touch. Each pad is saturated in brightening essence featuring 98% pure glutathione encapsulated in exosome-like particles for enhanced delivery. Niacinamide and vitamin C also visibly improve hyperpigmentation, post-acne marks, and uneven tone.

LHA gently sweeps away dulling dead skin cells, while panthenol, allantoin, beta-glucan, and madecassoside keep the formula soothing enough for daily use. The oversized 7 cm split pads hug the curves of the face for easy all-over or targeted care, leaving skin hydrated, smooth, and radiant without a sticky finish.

Highlights

• Targets dark spots, post-acne marks, uneven tone, and dullness
• Each jar contains 60 pads saturated in essence
• Oversized 7 cm split pads fit easily around the cheeks, chin, and T-zone
• Triple-layered pads hold plenty of essence from the first pad to the last
• Gently exfoliates while refining the look of pores and excess oil
• Suitable for all skin types, including sensitive and acne-prone skin

Clinical Results

• 9.43% improvement in deep hyperpigmentation after three days¹
• 17.81% improvement in deep hyperpigmentation after four weeks¹
• 3.63% improvement in surface hyperpigmentation after three days¹
• 9.74% improvement in surface hyperpigmentation after four weeks¹
• 2.03% immediate improvement in skin brightness²
• 2.82% immediate improvement in skin radiance²
• 8.67% immediate improvement in skin texture²

Key Ingredients

• Glutathiosome: 98% pure glutathione encapsulated in exosome-like particles enhance delivery to help visibly reduce dark spots and pigmentation.
• Niacinamide & Vitamin C: Brighten dull skin, improve uneven tone, and minimize the appearance of post-acne marks.
• LHA: Gently exfoliates dead skin cells and excess sebum for smoother texture and clearer-looking pores.
• Panthenol, Allantoin, Beta-Glucan & Madecassoside: Soothe, hydrate, and protect the skin from external irritants.

¹Based on a clinical study of 20 participants conducted by SKINMED Clinical Trials Center from April 1–May 7, 2024. Individual results may vary.
²Based on a clinical study of 20 participants conducted by P&K Skin Research Center from April 1–2, 2024. Results reflect immediate effects. Individual results may vary.